NLX-112, a ground-breaking, non-dopaminergic drug, exhibited both anti-dyskinetic and anti-parkinsonian properties in a proof-of-concept Phase 2A clinical trial. The positive findings were presented in July as a ‘Hot Topics’ oral presentation at the World Parkinson’s Congress in Barcelona, Spain (see video). They will also be presented at the forthcoming Movement Disorders Society Congress in Copenhagen, Denmark, on Wednesday, August 30 (Poster #1435). The dual clinical efficacy profile of NLX-112 arises from its innovative mechanism of action. Unlike most current anti-parkinsonian medications, NLX-112 does not target the dopaminergic system, and is a highly selective, serotonin 5-HT1A receptor activator. 
See the full press release.